Magnesium Trisilicate

Identification

Name
Magnesium Trisilicate
Accession Number
DB09281
Type
Small Molecule
Groups
Approved
Description

Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Magnesium trisilicate hydrateC2E1CI501T39365-87-2FSBVERYRVPGNGG-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Alka Phenyl TabMagnesium Trisilicate (150 mg) + Aluminum hydroxide (100 mg) + Phenylbutazone (100 mg)TabletOralDuchesnay Inc.1978-12-311997-08-11Canada
Alka Phenylbutazone TabMagnesium Trisilicate (150 mg) + Aluminum hydroxide (100 mg) + Phenylbutazone (100 mg)TabletOralPro Doc Limitee1974-12-311997-08-14Canada
Gasulsol TabMagnesium Trisilicate (130 mg) + Aluminum hydroxide (195 mg)TabletOralHerbes Universelles Inc.1966-12-312009-07-15Canada
GasvaMagnesium Trisilicate (487.5 mg) + Aluminum hydroxide (260 mg)TabletOralLes Produits Gerbex Inc.1970-12-311997-08-11Canada
Gaviscon Regular StrengthMagnesium Trisilicate (14.2 mg/1) + Aluminum hydroxide (80 mg/1)Tablet, chewableOralGlaxo Smith Kline Consumer Heathcare Lp2011-06-13Not applicableUs
Mag-A-folic TabMagnesium Trisilicate (100 mg) + Folic Acid (.4 mg) + Vitamin A (2000 unit)TabletOralMetagenics, Inc.1989-12-311996-10-02Canada
Phenylone Plus TabMagnesium Trisilicate (150 mg) + Aluminum hydroxide (100 mg) + Phenylbutazone (100 mg)TabletOralMedic Laboratory LtÉe1978-12-311996-09-09Canada
R90 Anti-acide TabMagnesium Trisilicate (500 mg) + Calcium Carbonate (300 mg)TabletOralDr Reckeweg Canada1993-12-311997-08-13Canada
Spasmo Nil TabMagnesium Trisilicate (75 mg) + Aluminum hydroxide (75 mg) + Dicyclomine Hydrochloride (2.5 mg) + Dimethicone (7.5 mg)TabletOralDuchesnay Inc.1978-12-312003-07-18Canada
Categories
UNII
FML8G1U0Y3
CAS number
14987-04-3
Weight
Average: 260.857
Monoisotopic: 259.86017997
Chemical Formula
Mg2O8Si3
InChI Key
GXGAKHNRMVGRPK-UHFFFAOYSA-N
InChI
InChI=1S/2Mg.O8Si3/c;;1-9(2)7-11(5,6)8-10(3)4/q2*+2;-4
IUPAC Name
dimagnesium(2+) ion {[dioxido({[oxido(oxo)silyl]oxy})silyl]oxy}silanoylolate
SMILES
[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O

Pharmacology

Indication

For the treatment of peptic ulcers. Relieving indigestion and heartburn.

Associated Conditions
Pharmacodynamics

Magnesium trisilicate works by increasing the pH of gastric juice via a neutralisation reaction. It also precipitates colloidal silica, which can coat gastrointestinal mucosa conferring further protection.

Mechanism of action

The gelatinous silicon dioxide, formed by the reaction of magnesium trisilicate with gastric contents is said to protect ulcerated mucosal surfaces and favor healing.

Absorption

The hydrated silicon dioxide formed in the stomach and passes into the intestinal track where, silica can be partly absorbed.

Volume of distribution

The hydrated silicon dioxide formed in the stomach and passes into the intestinal track.

Protein binding

33%

Metabolism
Not Available
Route of elimination

Excreted in the urine.

Half life

16-20 hours

Clearance

Maximum magnesium clearance is directly proportional to creatinine clearance.

Toxicity

Adequate doses of magnesium trisilicate may cause diarrhea due to the action of soluble magnesium salts in the enteric tract. Approx 5% of the magnesium is absorbed.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineMagnesium Trisilicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineMagnesium Trisilicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
3,4-MethylenedioxyamphetamineMagnesium Trisilicate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMagnesium Trisilicate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Magnesium Trisilicate.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Magnesium Trisilicate.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Magnesium Trisilicate.Experimental
AcepromazineMagnesium Trisilicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineMagnesium Trisilicate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetaminophenMagnesium Trisilicate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Magnesium Trisilicate.Approved, Vet Approved
AcetophenazineMagnesium Trisilicate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Acetylglycinamide chloral hydrate is combined with Magnesium Trisilicate.Experimental
AdinazolamThe risk or severity of adverse effects can be increased when Adinazolam is combined with Magnesium Trisilicate.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Magnesium Trisilicate.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Magnesium Trisilicate.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Alaproclate.Experimental
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Magnesium Trisilicate.Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be increased when used in combination with Magnesium Trisilicate.Experimental
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Magnesium Trisilicate.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium Trisilicate.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Magnesium Trisilicate.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Magnesium Trisilicate.Approved, Illicit
AlimemazineMagnesium Trisilicate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Allobarbital is combined with Magnesium Trisilicate.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Magnesium Trisilicate.Investigational
AllopurinolMagnesium Trisilicate can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlmotriptanThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Magnesium Trisilicate.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Magnesium Trisilicate.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Magnesium Trisilicate.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Alverine.Approved, Investigational
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Magnesium Trisilicate.Approved
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Magnesium Trisilicate.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Magnesium Trisilicate.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Magnesium Trisilicate.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Magnesium Trisilicate.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Magnesium Trisilicate.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Magnesium Trisilicate.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Magnesium Trisilicate.Experimental
AmphetamineMagnesium Trisilicate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Aniracetam is combined with Magnesium Trisilicate.Experimental
APD791The risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Apramycin is combined with Magnesium Trisilicate.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Aprobarbital is combined with Magnesium Trisilicate.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Apronalide is combined with Magnesium Trisilicate.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Arbaclofen Placarbil is combined with Magnesium Trisilicate.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Arbekacin is combined with Magnesium Trisilicate.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Magnesium Trisilicate.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Aripiprazole lauroxil is combined with Magnesium Trisilicate.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Magnesium Trisilicate.Approved
AtazanavirMagnesium Trisilicate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Magnesium Trisilicate.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium Trisilicate.Approved, Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium Trisilicate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Magnesium Trisilicate.Investigational, Vet Approved
AZD-3043The risk or severity of adverse effects can be increased when AZD-3043 is combined with Magnesium Trisilicate.Investigational
AzelastineMagnesium Trisilicate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Magnesium Trisilicate.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Barbexaclone is combined with Magnesium Trisilicate.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Magnesium Trisilicate.Illicit
BeclamideThe risk or severity of adverse effects can be increased when Beclamide is combined with Magnesium Trisilicate.Experimental
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
BekanamycinThe risk or severity of adverse effects can be increased when Bekanamycin is combined with Magnesium Trisilicate.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Magnesium Trisilicate.Withdrawn
BenazeprilMagnesium Trisilicate can cause a decrease in the absorption of Benazepril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
BenazeprilatMagnesium Trisilicate can cause a decrease in the absorption of Benazeprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Magnesium Trisilicate.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Magnesium Trisilicate.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Benzoctamine is combined with Magnesium Trisilicate.Approved
BenzphetamineMagnesium Trisilicate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Magnesium Trisilicate.Approved
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
BifemelaneThe risk or severity of adverse effects can be increased when Bifemelane is combined with Magnesium Trisilicate.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Magnesium Trisilicate.Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium Trisilicate.Approved
BL-1020Magnesium Trisilicate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Blonanserin is combined with Magnesium Trisilicate.Approved, Investigational
BosutinibMagnesium Trisilicate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Magnesium Trisilicate.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Magnesium Trisilicate.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Brivaracetam is combined with Magnesium Trisilicate.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Magnesium Trisilicate.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Magnesium Trisilicate.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Magnesium Trisilicate.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Magnesium Trisilicate.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Magnesium Trisilicate.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Magnesium Trisilicate.Approved, Investigational, Withdrawn
BudesonideThe bioavailability of Budesonide can be decreased when combined with Magnesium Trisilicate.Approved
BufotenineThe risk or severity of adverse effects can be increased when Bufotenine is combined with Magnesium Trisilicate.Experimental, Illicit
BuprenorphineMagnesium Trisilicate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Magnesium Trisilicate.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Magnesium Trisilicate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Magnesium Trisilicate.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Magnesium Trisilicate.Approved, Illicit
ButaperazineMagnesium Trisilicate can cause a decrease in the absorption of Butaperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Magnesium Trisilicate.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Magnesium Trisilicate.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Magnesium Trisilicate.Approved
CabergolineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Cabergoline.Approved
CamazepamThe risk or severity of adverse effects can be increased when Camazepam is combined with Magnesium Trisilicate.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Cannabidivarin is combined with Magnesium Trisilicate.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Capreomycin is combined with Magnesium Trisilicate.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Captodiame is combined with Magnesium Trisilicate.Approved, Investigational
CaptoprilMagnesium Trisilicate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Magnesium Trisilicate.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Magnesium Trisilicate.Approved
CarbromalThe risk or severity of adverse effects can be increased when Carbromal is combined with Magnesium Trisilicate.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Magnesium Trisilicate.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Magnesium Trisilicate.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Carisbamate is combined with Magnesium Trisilicate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Magnesium Trisilicate.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Magnesium Trisilicate.Withdrawn
CathinoneThe risk or severity of adverse effects can be increased when Cathinone is combined with Magnesium Trisilicate.Illicit
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium Trisilicate.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Magnesium Trisilicate.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Magnesium Trisilicate.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Magnesium Trisilicate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Magnesium Trisilicate.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Magnesium Trisilicate.Approved, Investigational, Withdrawn
ChloroquineMagnesium Trisilicate can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium Trisilicate.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Chlorphenesin is combined with Magnesium Trisilicate.Approved, Vet Approved, Withdrawn
ChlorphentermineMagnesium Trisilicate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineMagnesium Trisilicate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineMagnesium Trisilicate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Magnesium Trisilicate.Approved, Investigational, Withdrawn
ChlortetracyclineMagnesium Trisilicate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Magnesium Trisilicate.Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
CilansetronThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Cilansetron.Investigational
CilazaprilMagnesium Trisilicate can cause a decrease in the absorption of Cilazapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinitaprideThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Cinolazepam is combined with Magnesium Trisilicate.Approved
CisaprideThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe therapeutic efficacy of Cisatracurium can be increased when used in combination with Magnesium Trisilicate.Approved
CitalopramThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Magnesium Trisilicate.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Magnesium Trisilicate.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium Trisilicate.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Magnesium Trisilicate.Approved, Illicit
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium Trisilicate.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Magnesium Trisilicate.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Magnesium Trisilicate.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Magnesium Trisilicate.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
ClomocyclineMagnesium Trisilicate can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Magnesium Trisilicate.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Magnesium Trisilicate.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Magnesium Trisilicate.Experimental
CloprednolThe bioavailability of Cloprednol can be decreased when combined with Magnesium Trisilicate.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Magnesium Trisilicate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Magnesium Trisilicate.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Clotiazepam is combined with Magnesium Trisilicate.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when Cloxazolam is combined with Magnesium Trisilicate.Approved, Investigational
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Magnesium Trisilicate.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium Trisilicate.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Colistimethate is combined with Magnesium Trisilicate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Colistin is combined with Magnesium Trisilicate.Approved
CorticotropinThe bioavailability of Corticotropin can be decreased when combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
CortivazolThe bioavailability of Cortivazol can be decreased when combined with Magnesium Trisilicate.Investigational
CyamemazineMagnesium Trisilicate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Magnesium Trisilicate.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Cyclobarbital is combined with Magnesium Trisilicate.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Magnesium Trisilicate.Approved
CyclopentamineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Cyclopentamine.Withdrawn
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Magnesium Trisilicate.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Magnesium Trisilicate.Approved
CysteamineThe bioavailability of Cysteamine can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
Dabigatran etexilateMagnesium Trisilicate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DabrafenibMagnesium Trisilicate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Magnesium Trisilicate.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Magnesium Trisilicate.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Dapoxetine.Investigational
DasatinibMagnesium Trisilicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Deanol is combined with Magnesium Trisilicate.Experimental
DecamethoniumThe therapeutic efficacy of Decamethonium can be increased when used in combination with Magnesium Trisilicate.Approved
DeferiproneMagnesium Trisilicate can cause a decrease in the absorption of Deferiprone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
DelaprilMagnesium Trisilicate can cause a decrease in the absorption of Delapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
DelavirdineMagnesium Trisilicate can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Delorazepam is combined with Magnesium Trisilicate.Approved, Illicit, Investigational
DemeclocyclineMagnesium Trisilicate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Magnesium Trisilicate.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Magnesium Trisilicate.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Magnesium Trisilicate.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Magnesium Trisilicate.Approved, Investigational
DesonideThe bioavailability of Desonide can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Magnesium Trisilicate.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Magnesium Trisilicate.Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Magnesium Trisilicate.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium Trisilicate.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Magnesium Trisilicate.Approved, Vet Approved
DexmethylphenidateMagnesium Trisilicate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Dextofisopam is combined with Magnesium Trisilicate.Investigational
DextroamphetamineMagnesium Trisilicate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Magnesium Trisilicate.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Magnesium Trisilicate.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Magnesium Trisilicate.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Magnesium Trisilicate.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Dibekacin is combined with Magnesium Trisilicate.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Magnesium Trisilicate.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Magnesium Trisilicate.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Magnesium Trisilicate.Experimental
DiethylpropionMagnesium Trisilicate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Magnesium Trisilicate.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Magnesium Trisilicate.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Magnesium Trisilicate.Approved, Investigational, Withdrawn
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Magnesium Trisilicate.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Magnesium Trisilicate.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Magnesium Trisilicate.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Magnesium Trisilicate.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Magnesium Trisilicate.Investigational, Vet Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium Trisilicate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Magnesium Trisilicate.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Magnesium Trisilicate.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium Trisilicate.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Magnesium Trisilicate.Approved, Illicit
DixyrazineMagnesium Trisilicate can cause a decrease in the absorption of Dixyrazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DolasetronThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Dolasetron.Approved, Investigational
DolutegravirMagnesium Trisilicate can cause a decrease in the absorption of Dolutegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Domoic AcidThe risk or severity of adverse effects can be increased when Domoic Acid is combined with Magnesium Trisilicate.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Donepezil is combined with Magnesium Trisilicate.Approved
DopamineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Magnesium Trisilicate.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Magnesium Trisilicate.Approved
DotarizineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Dotarizine.Investigational
DoxacuriumThe therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium Trisilicate.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Doxefazepam is combined with Magnesium Trisilicate.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Magnesium Trisilicate.Approved, Investigational
DoxycyclineMagnesium Trisilicate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Magnesium Trisilicate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Magnesium Trisilicate.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Magnesium Trisilicate.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Magnesium Trisilicate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Magnesium Trisilicate.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Magnesium Trisilicate.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Magnesium Trisilicate.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Edivoxetine is combined with Magnesium Trisilicate.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Magnesium Trisilicate.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Magnesium Trisilicate.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Eltoprazine.Investigational
ElvitegravirMagnesium Trisilicate can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Magnesium Trisilicate.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Emylcamate is combined with Magnesium Trisilicate.Experimental
EnalaprilMagnesium Trisilicate can cause a decrease in the absorption of Enalapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
EnalaprilatMagnesium Trisilicate can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Magnesium Trisilicate.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Magnesium Trisilicate.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Ergotamine.Approved
ErlotinibMagnesium Trisilicate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Magnesium Trisilicate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Magnesium Trisilicate.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Esreboxetine is combined with Magnesium Trisilicate.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Magnesium Trisilicate.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Magnesium Trisilicate.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium Trisilicate.Approved, Investigational
EthadioneThe risk or severity of adverse effects can be increased when Ethadione is combined with Magnesium Trisilicate.Experimental
EthanolMagnesium Trisilicate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Magnesium Trisilicate.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Magnesium Trisilicate.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Magnesium Trisilicate.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Magnesium Trisilicate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Magnesium Trisilicate.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Magnesium Trisilicate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Magnesium Trisilicate.Approved, Illicit
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium Trisilicate.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Magnesium Trisilicate.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Etiracetam is combined with Magnesium Trisilicate.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Magnesium Trisilicate.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium Trisilicate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Magnesium Trisilicate.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Magnesium Trisilicate.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Magnesium Trisilicate.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Fabomotizole is combined with Magnesium Trisilicate.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Fazadinium bromide is combined with Magnesium Trisilicate.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Febarbamate is combined with Magnesium Trisilicate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Magnesium Trisilicate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Magnesium Trisilicate.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Magnesium Trisilicate.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Fenyramidol is combined with Magnesium Trisilicate.Experimental
Ferric ammonium citrateMagnesium Trisilicate can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CarboxymaltoseMagnesium Trisilicate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric cationMagnesium Trisilicate can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric hydroxideMagnesium Trisilicate can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric oxideMagnesium Trisilicate can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateMagnesium Trisilicate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric subsulfateMagnesium Trisilicate can cause a decrease in the absorption of Ferric subsulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Ferric sulfateMagnesium Trisilicate can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous bisglycinateMagnesium Trisilicate can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous chlorideMagnesium Trisilicate can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferrous fumarateMagnesium Trisilicate can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous gluconateMagnesium Trisilicate can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous succinateMagnesium Trisilicate can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous sulfateMagnesium Trisilicate can cause a decrease in the absorption of Ferrous sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
FerumoxidesMagnesium Trisilicate can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxsilMagnesium Trisilicate can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxytolMagnesium Trisilicate can cause a decrease in the absorption of Ferumoxytol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FexofenadineMagnesium Trisilicate can cause a decrease in the absorption of Fexofenadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Magnesium Trisilicate.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Magnesium Trisilicate.Experimental
FlucloroloneThe bioavailability of Fluclorolone can be decreased when combined with Magnesium Trisilicate.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Magnesium Trisilicate.Approved, Illicit
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium Trisilicate.Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Magnesium Trisilicate.Approved, Illicit
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
FluocortinThe bioavailability of Fluocortin can be decreased when combined with Magnesium Trisilicate.Experimental
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Magnesium Trisilicate.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Magnesium Trisilicate.Approved, Investigational, Withdrawn
FluperoloneThe bioavailability of Fluperolone can be decreased when combined with Magnesium Trisilicate.Experimental
FluphenazineMagnesium Trisilicate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Magnesium Trisilicate.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Magnesium Trisilicate.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium Trisilicate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Magnesium Trisilicate.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Magnesium Trisilicate.Approved, Investigational
FluticasoneThe bioavailability of Fluticasone can be decreased when combined with Magnesium Trisilicate.Approved, Experimental, Investigational
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium Trisilicate.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Magnesium Trisilicate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Fluvoxamine.Approved, Investigational
FormocortalThe bioavailability of Formocortal can be decreased when combined with Magnesium Trisilicate.Experimental
FosinoprilMagnesium Trisilicate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FosinoprilatMagnesium Trisilicate can cause a decrease in the absorption of Fosinoprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Magnesium Trisilicate.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Magnesium Trisilicate.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Framycetin is combined with Magnesium Trisilicate.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Magnesium Trisilicate.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Gaboxadol is combined with Magnesium Trisilicate.Investigational
GallamineThe therapeutic efficacy of Gallamine can be increased when used in combination with Magnesium Trisilicate.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be increased when used in combination with Magnesium Trisilicate.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Magnesium Trisilicate.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Gantacurium Chloride is combined with Magnesium Trisilicate.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Gedocarnil is combined with Magnesium Trisilicate.Experimental
GefitinibMagnesium Trisilicate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GeneticinThe risk or severity of adverse effects can be increased when Geneticin is combined with Magnesium Trisilicate.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Gentamicin is combined with Magnesium Trisilicate.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with GENTAMICIN C1A.Experimental
GepefrineMagnesium Trisilicate may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Magnesium Trisilicate.Investigational
GleptoferronMagnesium Trisilicate can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Magnesium Trisilicate.Approved, Illicit
GranisetronThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Magnesium Trisilicate.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Magnesium Trisilicate.Approved, Illicit, Withdrawn
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Magnesium Trisilicate.Approved, Investigational, Withdrawn
HalometasoneThe bioavailability of Halometasone can be decreased when combined with Magnesium Trisilicate.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Magnesium Trisilicate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Magnesium Trisilicate.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Magnesium Trisilicate.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Heptabarbital is combined with Magnesium Trisilicate.Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Magnesium Trisilicate.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Hexafluronium is combined with Magnesium Trisilicate.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Hexapropymate is combined with Magnesium Trisilicate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Magnesium Trisilicate.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Magnesium Trisilicate.Experimental
HydrocodoneMagnesium Trisilicate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
Hydrocortisone aceponateThe bioavailability of Hydrocortisone aceponate can be decreased when combined with Magnesium Trisilicate.Experimental, Vet Approved
Hydrocortisone acetateThe bioavailability of Hydrocortisone acetate can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
Hydrocortisone butyrateThe bioavailability of Hydrocortisone butyrate can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
Hydrocortisone probutateThe bioavailability of Hydrocortisone probutate can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
Hydrocortisone succinateThe bioavailability of Hydrocortisone succinate can be decreased when combined with Magnesium Trisilicate.Approved
Hydrocortisone valerateThe bioavailability of Hydrocortisone valerate can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Magnesium Trisilicate.Approved, Illicit
HydroxyamphetamineMagnesium Trisilicate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Magnesium Trisilicate.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Hygromycin B is combined with Magnesium Trisilicate.Vet Approved
HyoscyamineMagnesium Trisilicate can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Magnesium Trisilicate.Investigational
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
IdalopirdineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Idalopirdine.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Magnesium Trisilicate.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Magnesium Trisilicate.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Imagabalin is combined with Magnesium Trisilicate.Investigational
ImidaprilMagnesium Trisilicate can cause a decrease in the absorption of Imidapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Magnesium Trisilicate.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Imipramine oxide is combined with Magnesium Trisilicate.Experimental
Incadronic acidThe serum concentration of Incadronic acid can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
IndalpineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Magnesium Trisilicate.Investigational
Iofetamine I-123Magnesium Trisilicate may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Magnesium Trisilicate.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Magnesium Trisilicate.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Magnesium Trisilicate.Withdrawn
IronMagnesium Trisilicate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranMagnesium Trisilicate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron isomaltoside 1000Magnesium Trisilicate can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iron saccharateMagnesium Trisilicate can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsepamicinThe risk or severity of adverse effects can be increased when Isepamicin is combined with Magnesium Trisilicate.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Magnesium Trisilicate.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Magnesium Trisilicate.Approved, Vet Approved
ItraconazoleMagnesium Trisilicate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Kanamycin is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium Trisilicate.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Magnesium Trisilicate.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Magnesium Trisilicate.Approved, Investigational
KetoconazoleMagnesium Trisilicate can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium Trisilicate.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Lacosamide is combined with Magnesium Trisilicate.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium Trisilicate.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Lanicemine is combined with Magnesium Trisilicate.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Lasmiditan.Investigational
LedipasvirMagnesium Trisilicate can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Magnesium Trisilicate.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Magnesium Trisilicate.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Magnesium Trisilicate.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Magnesium Trisilicate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Magnesium Trisilicate.Approved
LincomycinThe risk or severity of adverse effects can be increased when Lincomycin is combined with Magnesium Trisilicate.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Linezolid.Approved, Investigational
LisdexamfetamineMagnesium Trisilicate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LisinoprilMagnesium Trisilicate can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Lithium cation is combined with Magnesium Trisilicate.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Magnesium Trisilicate.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Magnesium Trisilicate.Experimental
LofexidineThe therapeutic efficacy of Magnesium Trisilicate can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Magnesium Trisilicate.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium Trisilicate.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Magnesium Trisilicate.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Magnesium Trisilicate.Approved
LorpiprazoleThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Lortalamine is combined with Magnesium Trisilicate.Experimental
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Magnesium Trisilicate.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Magnesium Trisilicate.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Lumateperone is combined with Magnesium Trisilicate.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Magnesium Trisilicate.Approved, Investigational
LymecyclineMagnesium Trisilicate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Magnesium Trisilicate.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Magnesium glycinate is combined with Magnesium Trisilicate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Magnesium silicate is combined with Magnesium Trisilicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Magnesium Trisilicate can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Magnesium Trisilicate.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Mazindol is combined with Magnesium Trisilicate.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Magnesium Trisilicate.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Magnesium Trisilicate.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Mebutamate is combined with Magnesium Trisilicate.Approved
MecamylamineMagnesium Trisilicate may decrease the excretion rate of Mecamylamine which could result in a higher serum level.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Magnesium Trisilicate.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Magnesium Trisilicate.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Magnesium Trisilicate.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Medifoxamine is combined with Magnesium Trisilicate.Experimental
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Magnesium Trisilicate.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Magnesium Trisilicate.Approved, Nutraceutical, Vet Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Magnesium Trisilicate.Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Magnesium Trisilicate.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Magnesium Trisilicate.Approved, Investigational
MemantineMagnesium Trisilicate may decrease the excretion rate of Memantine which could result in a higher serum level.Approved, Investigational
MephedroneMagnesium Trisilicate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Mephenesin is combined with Magnesium Trisilicate.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Mephenoxalone is combined with Magnesium Trisilicate.Experimental
MephentermineMagnesium Trisilicate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Mephenytoin is combined with Magnesium Trisilicate.Investigational, Withdrawn
MeprednisoneThe bioavailability of Meprednisone can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Magnesium Trisilicate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Magnesium Trisilicate.Experimental
MesalazineMagnesium Trisilicate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MesoridazineMagnesium Trisilicate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Magnesium Trisilicate.Approved
MetergolineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Metergoline.Experimental
MethacyclineMagnesium Trisilicate can cause a decrease in the absorption of Methacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Magnesium Trisilicate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Magnesium Trisilicate.Approved, Illicit
MethamphetamineMagnesium Trisilicate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Magnesium Trisilicate.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Magnesium Trisilicate.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Metharbital is combined with Magnesium Trisilicate.Withdrawn
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Magnesium Trisilicate.Approved, Vet Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Magnesium Trisilicate.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Magnesium Trisilicate.Approved
MethotrimeprazineMagnesium Trisilicate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
MethoxyphenamineMagnesium Trisilicate may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium Trisilicate.Approved
Methylene blueMagnesium Trisilicate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Methylpentynol is combined with Magnesium Trisilicate.Experimental
MethylphenidateMagnesium Trisilicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Magnesium Trisilicate.Approved
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
MethyprylonThe risk or severity of adverse effects can be increased when Methyprylon is combined with Magnesium Trisilicate.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Methysergide.Approved
MetocurineThe therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium Trisilicate.Approved
Metocurine IodideThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Magnesium Trisilicate.Approved, Withdrawn
MetyrosineMagnesium Trisilicate may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Mianserin is combined with Magnesium Trisilicate.Approved, Investigational
MicronomicinThe risk or severity of adverse effects can be increased when Micronomicin is combined with Magnesium Trisilicate.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Magnesium Trisilicate.Approved, Illicit
MidomafetamineMagnesium Trisilicate may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Magnesium Trisilicate.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Magnesium Trisilicate.Approved, Investigational
MirtazapineMagnesium Trisilicate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MisoprostolThe serum concentration of Misoprostol can be decreased when it is combined with Magnesium Trisilicate.Approved
MivacuriumThe therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium Trisilicate.Approved
MK-212The risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with MK-212.Investigational
MMDAMagnesium Trisilicate may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Magnesium Trisilicate.Approved, Investigational
MoexiprilMagnesium Trisilicate can cause a decrease in the absorption of Moexipril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Magnesium Trisilicate.Approved
MometasoneThe bioavailability of Mometasone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
Mometasone furoateThe bioavailability of Mometasone furoate can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
MoperoneThe risk or severity of adverse effects can be increased when Moperone is combined with Magnesium Trisilicate.Experimental
MoricizineMagnesium Trisilicate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Magnesium Trisilicate.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Mosapramine is combined with Magnesium Trisilicate.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when MRK-409 is combined with Magnesium Trisilicate.Experimental
Mycophenolic acidMagnesium Trisilicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Magnesium Trisilicate.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Magnesium Trisilicate.Approved
NaluzotanThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Neamine is combined with Magnesium Trisilicate.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Magnesium Trisilicate.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Neocitrullamon is combined with Magnesium Trisilicate.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Neomycin is combined with Magnesium Trisilicate.Approved, Vet Approved
NeosaxitoxinThe therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Magnesium Trisilicate.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Netilmicin is combined with Magnesium Trisilicate.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Magnesium Trisilicate.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Niaprazine is combined with Magnesium Trisilicate.Experimental
NicotineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Nicotine.Approved
NilotinibMagnesium Trisilicate can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Nisoxetine is combined with Magnesium Trisilicate.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Magnesium Trisilicate.Approved
NitrofurantoinThe serum concentration of Nitrofurantoin can be decreased when it is combined with Magnesium Trisilicate.Approved, Vet Approved
NitroprussideMagnesium Trisilicate can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Magnesium Trisilicate.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Nomifensine is combined with Magnesium Trisilicate.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Magnesium Trisilicate.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Magnesium Trisilicate.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Magnesium Trisilicate.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Magnesium Trisilicate.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Magnesium Trisilicate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium Trisilicate.Approved
OmapatrilatMagnesium Trisilicate can cause a decrease in the absorption of Omapatrilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Magnesium Trisilicate.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Magnesium Trisilicate.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Magnesium Trisilicate.Approved, Illicit
OrphenadrineMagnesium Trisilicate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Orvepitant is combined with Magnesium Trisilicate.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Magnesium Trisilicate.Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Oxaflozane is combined with Magnesium Trisilicate.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Magnesium Trisilicate.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Magnesium Trisilicate.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Magnesium Trisilicate.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Oxiracetam is combined with Magnesium Trisilicate.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Oxitriptan is combined with Magnesium Trisilicate.Approved, Investigational, Nutraceutical
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Magnesium Trisilicate.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium Trisilicate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Oxypertine is combined with Magnesium Trisilicate.Experimental
OxytetracyclineMagnesium Trisilicate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Magnesium Trisilicate.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Palonosetron.Approved, Investigational
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium Trisilicate.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be increased when used in combination with Magnesium Trisilicate.Approved
ParaldehydeMagnesium Trisilicate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Paramethadione is combined with Magnesium Trisilicate.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Magnesium Trisilicate.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Magnesium Trisilicate.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium Trisilicate.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Paroxetine.Approved, Investigational
PazopanibMagnesium Trisilicate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenbutololThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Magnesium Trisilicate.Experimental
PenicillamineMagnesium Trisilicate can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenimepicyclineMagnesium Trisilicate can cause a decrease in the absorption of Penimepicycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Magnesium Trisilicate.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Magnesium Trisilicate.Approved
PerazineMagnesium Trisilicate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerflubutaneMagnesium Trisilicate can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilMagnesium Trisilicate can cause a decrease in the absorption of Perindopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PerindoprilatMagnesium Trisilicate can cause a decrease in the absorption of Perindoprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Magnesium Trisilicate.Approved
PerphenazineMagnesium Trisilicate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Magnesium Trisilicate.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Phenacemide is combined with Magnesium Trisilicate.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Magnesium Trisilicate.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Phencyclidine is combined with Magnesium Trisilicate.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Magnesium Trisilicate.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Phenethylamine is combined with Magnesium Trisilicate.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Pheneturide is combined with Magnesium Trisilicate.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Magnesium Trisilicate.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Magnesium Trisilicate.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium Trisilicate.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Magnesium Trisilicate.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Magnesium Trisilicate.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Phenprobamate is combined with Magnesium Trisilicate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Phensuximide is combined with Magnesium Trisilicate.Approved
PhentermineMagnesium Trisilicate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Magnesium Trisilicate.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Piclozotan.Investigational
PimavanserinThe risk or severity of adverse effects can be increased when Pimavanserin is combined with Magnesium Trisilicate.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Magnesium Trisilicate.Approved
PinazepamThe risk or severity of adverse effects can be increased when Pinazepam is combined with Magnesium Trisilicate.Experimental
PindololThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Magnesium Trisilicate.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium Trisilicate.Approved
PipotiazineMagnesium Trisilicate can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Magnesium Trisilicate.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Pirlimycin is combined with Magnesium Trisilicate.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Magnesium Trisilicate.Approved
PivagabineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Magnesium Trisilicate.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Magnesium Trisilicate.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Magnesium Trisilicate.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Plazomicin is combined with Magnesium Trisilicate.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Polymyxin B Sulfate is combined with Magnesium Trisilicate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Magnesium Trisilicate.Approved
PramipexoleMagnesium Trisilicate may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Magnesium Trisilicate.Approved, Illicit
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Magnesium Trisilicate.Approved, Investigational
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
PrednylideneThe bioavailability of Prednylidene can be decreased when combined with Magnesium Trisilicate.Experimental
PregabalinThe therapeutic efficacy of Magnesium Trisilicate can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Pridinol is combined with Magnesium Trisilicate.Experimental
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Magnesium Trisilicate.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Procainamide is combined with Magnesium Trisilicate.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Magnesium Trisilicate.Approved, Investigational
ProchlorperazineMagnesium Trisilicate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Progabide is combined with Magnesium Trisilicate.Approved, Investigational
PromazineMagnesium Trisilicate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineMagnesium Trisilicate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Magnesium Trisilicate.Experimental
PropericiazineMagnesium Trisilicate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Propiomazine is combined with Magnesium Trisilicate.Approved
PropiopromazineMagnesium Trisilicate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Magnesium Trisilicate.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Magnesium Trisilicate.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Magnesium Trisilicate.Experimental
Prussian blueMagnesium Trisilicate can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PRX-08066The risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with PRX-08066.Investigational
PseudoephedrineMagnesium Trisilicate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Psilocybine is combined with Magnesium Trisilicate.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Puromycin is combined with Magnesium Trisilicate.Experimental
PyrantelThe therapeutic efficacy of Pyrantel can be increased when used in combination with Magnesium Trisilicate.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Pyrithyldione is combined with Magnesium Trisilicate.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Magnesium Trisilicate.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Magnesium Trisilicate.Approved
QuinaprilMagnesium Trisilicate can cause a decrease in the absorption of Quinapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinaprilatMagnesium Trisilicate can cause a decrease in the absorption of Quinaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
QuinidineMagnesium Trisilicate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
QuinineMagnesium Trisilicate can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Quinupramine is combined with Magnesium Trisilicate.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Magnesium Trisilicate.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Magnesium Trisilicate.Approved, Investigational
RamiprilMagnesium Trisilicate can cause a decrease in the absorption of Ramipril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RamiprilatMagnesium Trisilicate can cause a decrease in the absorption of Ramiprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
RamosetronThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Ramosetron.Approved, Investigational
RapacuroniumThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium Trisilicate.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Magnesium Trisilicate.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Reboxetine is combined with Magnesium Trisilicate.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Remacemide is combined with Magnesium Trisilicate.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Magnesium Trisilicate.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Magnesium Trisilicate.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Reposal is combined with Magnesium Trisilicate.Approved
RescinnamineMagnesium Trisilicate can cause a decrease in the absorption of Rescinnamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Magnesium Trisilicate.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Ribostamycin is combined with Magnesium Trisilicate.Approved, Investigational
RifampicinMagnesium Trisilicate can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RiluzoleThe risk or severity of adverse effects can be increased when Riluzole is combined with Magnesium Trisilicate.Approved, Investigational
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Magnesium Trisilicate.Approved
RiociguatMagnesium Trisilicate can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Magnesium Trisilicate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Ritanserin.Investigational
RitobegronMagnesium Trisilicate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Rizatriptan.Approved
RocuroniumThe therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium Trisilicate.Approved
RolipramThe risk or severity of adverse effects can be increased when Rolipram is combined with Magnesium Trisilicate.Investigational
RolitetracyclineMagnesium Trisilicate can cause a decrease in the absorption of Rolitetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Magnesium Trisilicate.Vet Approved
RopiniroleMagnesium Trisilicate may increase the sedative activities of Ropinirole.Approved, Investigational
RosuvastatinMagnesium Trisilicate can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RotigotineMagnesium Trisilicate may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when RP-5063 is combined with Magnesium Trisilicate.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Magnesium Trisilicate.Approved
SafinamideThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Magnesium Trisilicate.Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when Saredutant is combined with Magnesium Trisilicate.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium Trisilicate.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Magnesium Trisilicate.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Magnesium Trisilicate.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Magnesium Trisilicate.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Sibutramine is combined with Magnesium Trisilicate.Approved, Illicit, Investigational, Withdrawn
SisomicinThe risk or severity of adverse effects can be increased when Sisomicin is combined with Magnesium Trisilicate.Investigational
Sodium feredetateMagnesium Trisilicate can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Magnesium Trisilicate.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Magnesium Trisilicate.Approved
SpiraprilMagnesium Trisilicate can cause a decrease in the absorption of Spirapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
St. John's WortThe risk or severity of adverse effects can be increased when St. John's Wort is combined with Magnesium Trisilicate.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Magnesium Trisilicate.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Streptomycin is combined with Magnesium Trisilicate.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Styramate is combined with Magnesium Trisilicate.Experimental
SuccinylcholineThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium Trisilicate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Magnesium Trisilicate.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be increased when used in combination with Magnesium Trisilicate.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Sulthiame is combined with Magnesium Trisilicate.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Magnesium Trisilicate.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Sumatriptan.Approved, Investigational
SuvorexantMagnesium Trisilicate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Talbutal is combined with Magnesium Trisilicate.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Talopram is combined with Magnesium Trisilicate.Experimental
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Magnesium Trisilicate.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Magnesium Trisilicate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Magnesium Trisilicate.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Tegaserod.Approved, Investigational, Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Magnesium Trisilicate.Approved, Investigational
TemocaprilMagnesium Trisilicate can cause a decrease in the absorption of Temocapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
TetracyclineMagnesium Trisilicate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TetraethylammoniumThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Tetraethylammonium.Experimental, Investigational
Tetraferric tricitrate decahydrateMagnesium Trisilicate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Magnesium Trisilicate.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Tetrazepam is combined with Magnesium Trisilicate.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Magnesium Trisilicate.Investigational
ThalidomideMagnesium Trisilicate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Magnesium Trisilicate.Approved, Vet Approved
ThiazinamMagnesium Trisilicate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineMagnesium Trisilicate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Magnesium Trisilicate.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Magnesium Trisilicate.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Thiopropazate is combined with Magnesium Trisilicate.Experimental
ThioproperazineMagnesium Trisilicate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThioridazineMagnesium Trisilicate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Magnesium Trisilicate.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Magnesium Trisilicate.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Magnesium Trisilicate.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Magnesium Trisilicate.Approved, Investigational
TigecyclineMagnesium Trisilicate can cause a decrease in the absorption of Tigecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Magnesium Trisilicate.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Magnesium Trisilicate.Experimental
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Magnesium Trisilicate.Approved, Withdrawn
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Magnesium Trisilicate.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Tobramycin is combined with Magnesium Trisilicate.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Tofisopam is combined with Magnesium Trisilicate.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Magnesium Trisilicate.Approved, Withdrawn
TolevamerThe therapeutic efficacy of Tolevamer can be decreased when used in combination with Magnesium Trisilicate.Approved, Investigational
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Magnesium Trisilicate.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Tolperisone is combined with Magnesium Trisilicate.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium Trisilicate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Magnesium Trisilicate.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Tramiprosate is combined with Magnesium Trisilicate.Investigational
TrandolaprilMagnesium Trisilicate can cause a decrease in the absorption of Trandolapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium Trisilicate.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Trazodone.Approved, Investigational
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Magnesium Trisilicate.Approved, Vet Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Magnesium Trisilicate.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Magnesium Trisilicate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Magnesium Trisilicate.Approved
TriclofosThe risk or severity of adverse effects can be increased when Triclofos is combined with Magnesium Trisilicate.Withdrawn
TriethylenetetramineMagnesium Trisilicate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TrifluoperazineMagnesium Trisilicate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Magnesium Trisilicate.Experimental
TriflupromazineMagnesium Trisilicate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrilostaneThe bioavailability of Trilostane can be decreased when combined with Magnesium Trisilicate.Approved, Investigational, Vet Approved, Withdrawn
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Magnesium Trisilicate.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Trimethaphan.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Magnesium Trisilicate.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Magnesium Trisilicate.Approved
TropisetronThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Tropisetron.Approved, Investigational
TubocurarineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Tubocurarine.Approved
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Magnesium Trisilicate.Approved
UrapidilThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Vabicaserin.Investigational
ValerianThe risk or severity of adverse effects can be increased when Valerian is combined with Magnesium Trisilicate.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Valnoctamide is combined with Magnesium Trisilicate.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Magnesium Trisilicate.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Valpromide is combined with Magnesium Trisilicate.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium Trisilicate.Approved
VecuroniumThe therapeutic efficacy of Vecuronium can be increased when used in combination with Magnesium Trisilicate.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Magnesium Trisilicate.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Magnesium Trisilicate.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Magnesium Trisilicate.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Viloxazine is combined with Magnesium Trisilicate.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Vinbarbital is combined with Magnesium Trisilicate.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Magnesium Trisilicate.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Magnesium Trisilicate.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Vinylbital is combined with Magnesium Trisilicate.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Magnesium Trisilicate.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Wortmannin.Experimental
XP19986The risk or severity of adverse effects can be increased when XP19986 is combined with Magnesium Trisilicate.Investigational
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Magnesium Trisilicate.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Magnesium Trisilicate.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Magnesium Trisilicate.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Magnesium Trisilicate.Approved
ZofenoprilMagnesium Trisilicate can cause a decrease in the absorption of Zofenopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Magnesium Trisilicate.Vet Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium Trisilicate.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Zolmitriptan.Approved, Investigational
ZolpidemMagnesium Trisilicate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium Trisilicate.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Magnesium Trisilicate.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Magnesium Trisilicate.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Magnesium Trisilicate.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Toxnet [Link]
  2. Toxnet [Link]
  3. Sciencedirect [Link]
External Links
KEGG Drug
D03271
PubChem Compound
5311266
PubChem Substance
310265174
ChemSpider
4470779
ChEMBL
CHEMBL2096633
Wikipedia
Magnesium_trisilicate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, chewableOral
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-2.7ChemAxon
pKa (Strongest Acidic)2.65ChemAxon
pKa (Strongest Basic)-7.7ChemAxon
Physiological Charge-4ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area144.84 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity11.36 m3·mol-1ChemAxon
Polarizability11.91 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal silicates. These are inorganic compounds in which the largest oxoanion is silicate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal oxoanionic compounds
Sub Class
Alkaline earth metal silicates
Direct Parent
Alkaline earth metal silicates
Alternative Parents
Miscellaneous silicates / Metalloid salts / Inorganic salts / Inorganic oxides
Substituents
Silicate / Alkaline earth metal silicate / Inorganic oxide / Inorganic salt / Inorganic metalloid salt
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 29, 2015 09:58 / Updated on August 02, 2018 07:58